On this page

Meeting

COT Meeting: 2nd July 2019

Agenda and papers for the meeting of the Committee at 10.00am on Tuesday, 2nd July 2019 in Broadway House Conference Centre, Tothill St, London, SW1H 9NQ.

Last updated: 06 July 2021

View as PDF

On this page

Meeting Agenda

  1. Apologies for absence
  2. Draft minutes of May meeting TOX/MIN/2019/03
  3. Matters arising: Polycyclic aromatic hydrocarbons (PAHs) TOX/2019/27, Exposure to fumonisins TOX/2019/28, Genotoxicity of MCPD  TOX/2019/29 and Mycotoxins TOX/2019/30 
  4. Male reproductive toxicity of a novel feed additive, 3-nitro-oxypropanol (3-NOP): benchmark dose modelling report (Reserved Business). TOX/2019/31
  5. Scoping paper on the potential adverse effects of CBD products. TOX/2019/32
  6. Additional data regarding Fusarenon-X in the diet of infants aged 0 to 12 months and children aged 1 to 5 years. TOX/2019/33
  7. Review of physiologically-based pharmacokinetic (PBPK) modelling used for human health risk assessment. TOX/2019/34
  8. Scoping paper on the synthesis and integration of epidemiological and toxicological evidence in risk assessments. TOX/2019/35
  9. Discussion paper on potential risks from various sweeteners in the diet of infants aged 0 to 12 months and children aged 1 to 5 years. TOX/2019/36
  10. Potential toxicological risks from electronic nicotine (and non-nicotine) delivery systems (E(N)NDS – e-cigarettes)
    a) Decision tree for risk assessing flavouring compounds in E(N)NDS TOX/2019/37
    b) Toxicological review of nicotine TOX/2019/38
    c) User exposure TOX/2019/39 
  11. Update paper for information: FSA Scientific Advisory Committees (SACs) update. TOX/2019/40
  12. Any other business

Date of next meeting Tuesday 17th September 2019 at Broadway House Conference Centre, Tothill St, London, SW1H 9NQ.   

Media discussed during the meeting

TOX 2019 - 27

Scoping paper on the potential risks from polycyclic aromatic hydrocarbons (PAHs) in the diet of infants aged 0 to 12 months and children aged 1 to 5 years

TOX 2019 - 28

Exposure estimates from a possible source of exposure for fumonisins via consumption of infant formula

TOX 2019 - 29

Review of potential risks from 2-(monochloropropanediol (MCPD), 3-MCPD and glycidol and their fatty acid esters in the diet of infants aged 0 to 12 months and children aged 1 to 5 years

TOX 2019 - 30

Review of potential risks from contaminants in the diet of infants aged 0 to 12 months and children aged 1 to 5 years - mycotoxins

TOX 2019 - 32

Scoping paper on the potential adverse effects of CBD products

TOX 2019 - 33

Additional data regarding Fusarenon-X in the diet of infants aged 0 to 12 months and children aged 1 to 5 years

TOX 2019 - 34

Review of physiologically-based pharmacokinetic (PBPK) modelling used for human health risk assessment.

TOX 2019 - 35

Scoping paper on the synthesis and integration of epidemiological and toxicological evidence in risk assessments

TOX 2019 - 36

Discussion paper on potential risks from various sweeteners in the diet of infants aged 0 to 12 months and children aged 1 to 5 years

TOX 2019 - 37

Potential toxicological risks from electronic nicotine (and non-nicotine) delivery systems (E(N)NDS – e-cigarettes). Paper 11: Decision tree for risk assessing flavouring compounds in E(N)NDS

TOX 2019 - 38

Potential toxicological risks from electronic nicotine (and non-nicotine) delivery systems (E(N)NDS – e-cigarettes). Paper 12: Toxicological review of nicotine.

TOX 2019 - 39

Potential toxicological risks from electronic nicotine (and non-nicotine) delivery systems (E(N)NDS – e-cigarettes). Paper 13: User exposure.

Final minutes of the meeting of the Committee on 2nd July 2019

The final minutes of the meeting of the Committee held on 2nd July 2019 at Broadway House Conference Centre, Tothill St, London, SW1H 9NQ.